Equities researchers at StockNews.com initiated coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Get Free Report) in a research report issued on Saturday. The brokerage set a “sell” rating on the stock.
Navidea Biopharmaceuticals Trading Down 50.0 %
NYSE:NAVB opened at $0.00 on Friday. Navidea Biopharmaceuticals has a 12 month low of $0.00 and a 12 month high of $0.13.
Navidea Biopharmaceuticals Company Profile
See Also
- Five stocks we like better than Navidea Biopharmaceuticals
- Growth Investing: Should You Adopt This Investing Strategy in 2022?
- How to Build the Ultimate Everything ETF Portfolio
- What Are Earnings Reports?
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- P/E Ratio Calculation: How to Assess Stocks
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.